Action KIN KINDRED BIOSCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Kindred Biosciences, Inc.

Actions

KIN

US4945771099

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Kindred Biosciences : Market Offering Agreement (Form 8-K)
PU
KINDRED BIOSCIENCES, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)
AQ
KINDRED BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Kindred Bio: Q2 Earnings Snapshot
AQ
KINDRED BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
KINDRED BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
KINDRED BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
KINDRED BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
KINDRED BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kindred Biosciences, Inc. - KIN
BU
Kindred Biosciences : FORM OF SUPPORT AGREEMENT (Form 8-K)
PU
KINDRED BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Kindred Biosciences : Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus
AQ
Kindred Biosciences : Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus (Form 8-K)
PU
KINDRED BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Kindred Biosciences : to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XI
PR
Kindred Bio: Q1 Earnings Snapshot
AQ
KINDRED BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
KINDRED BIOSCIENCES, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
Kindred Biosciences : Announces First Quarter 2021 Financial Results
PR
Kindred Biosciences : Announces First Quarter 2021 Financial Results (Form 8-K)
PU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action KIN
  4. Actualités Kindred Biosciences, Inc.
  5. Communiqués